tirzepatide legal battle between makers of rival GLP-1 drugs over claims made in advertisements Novo sues Lilly, claiming misleading

Keywords: GLP-1 receptor agonists, type 2 diabetes mellitus, obesity management, incretin hormones, molecular pharmacology Introduction The increasing global prevalence of type two diabetes mellitus (DM2) and obesity has brought them to the forefront of public health challenges

More broadly, the fact that one of the worlds largest AI startups is establishing a new team to interact with the startup community, highlights a shift towards developing AI for builders needs, rather than one-size-fits-all proprietary solutions

In a separate announcement also on Tuesday, Novo touted nearly 20% weight loss after 24 weeks for its United Biotechnologypartnered triple-G agonist

IMPORTANT INFORMATION ABOUT COMPOUNDED MEDICATIONS This medication has been compounded (custom-prepared) by a pharmacy

Take our weight-loss assessment

Vitamin D deficiency is common in the UK, particularly during winter months, and can cause musculoskeletal pain and weakness